Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
High Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor Expressing Neuroendocrine Neoplasms.
Sponsor: CHI St. Luke's Health, Texas
This PHASE2/PHASE3 trial investigates Neuroendocrine Tumors and is currently completed. CHI St. Luke's Health, Texas leads this study, which shows 10 recorded versions since 2005 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
May 2023 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Apr 2023 — May 2023 [monthly]
Completed PHASE2_PHASE3
-
Jan 2021 — Apr 2023 [monthly]
Completed PHASE2_PHASE3
▶ Show 5 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
-
May 2017 — Feb 2018 [monthly]
Completed PHASE2_PHASE3
Status: Unknown Status → Completed
-
Feb 2017 — May 2017 [monthly]
Unknown Status PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2_PHASE3
First recorded
Aug 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CHI St. Luke's Health, Texas
- Excel Diagnostic Imaging Clinics
- Radio Isotope Therapy of America
- Radiomedix, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .